We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+40.65%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.13B
AUM Growth
+$681M
(+28%)
Cap. Flow
-$365M
Cap. Flow
% of AUM
-11.64%
Top 10 Holdings %
Top 10 Hldgs %
43.55%
Holding
107
New
15
Increased
23
Reduced
25
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AdaptHealth
AHCO
|
+$171M |
| 2 |
Tandem Diabetes Care
TNDM
|
+$55.9M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
+$37.8M |
| 4 |
Korro Bio
KRRO
|
+$22.1M |
| 5 |
Ardelyx
ARDX
|
+$21.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AERI
Aerie Pharmaceuticals
AERI
|
+$57.9M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$52.7M |
| 3 |
Coherus Oncology
CHRS
|
+$31.2M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$26.3M |
| 5 |
DFBHU
DFB Healthcare Acquisitions Corp. Unit
DFBHU
|
+$25.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.62% |
| 2 | Financials | 0.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alector
ALEC
$167M
| $35.8M | 1.14% |
2,076,812
| – | – |
|
27
Editas Medicine
EDIT
$457M
| $34.3M | 1.09% |
1,158,841
| – | – |
|
|
SWTX
28
DELISTED
SpringWorks Therapeutics
SWTX
| $30.3M | 0.97% |
788,243
-262,645
| -25% | -$6.15M |
|
29
Humana
HUM
$48B
| $30.1M | 0.96% |
82,000
+15,000
| +22% | +$4.76M |
|
|
BOLD
30
DELISTED
Audentes Therapeutics, Inc
BOLD
| $29.6M | 0.94% |
493,901
| – | – |
|
31
argenx
ARGX
$53.8B
| $29.5M | 0.94% |
184,000
-97,000
| -35% | -$13.1M |
|
32
Sarepta Therapeutics
SRPT
$1.82B
| $27.1M | 0.86% |
210,000
-172,000
| -45% | -$17.4M |
|
|
CNST
33
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $25.9M | 0.83% |
550,000
+526,400
| +2,231% | +$15.2M |
|
|
34
Korro Bio
KRRO
$177M
| $24.9M | 0.79% |
+28,373
| New | +$22.1M |
|
|
TECX
35
Tectonic Therapeutic
TECX
$615M
| $23.5M | 0.75% |
97,081
+55,414
| +133% | +$10.7M |
|
|
AXNX
36
DELISTED
Axonics, Inc. Common Stock
AXNX
| $23.2M | 0.74% |
+837,945
| New | +$20M |
|
|
TPTX
37
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $22.8M | 0.73% |
366,000
-21,545
| -6% | -$1.03M |
|
38
Cabaletta Bio
CABA
$461M
| $22.8M | 0.73% |
+1,628,504
| New | +$19.3M |
|
|
MRTX
39
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $22.4M | 0.72% |
174,000
-59,000
| -25% | -$5.69M |
|
40
BioCryst Pharmaceuticals
BCRX
$2.36B
| $22M | 0.7% |
6,375,143
+3,600,500
| +130% | +$9.06M |
|
|
RETA
41
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $20.4M | 0.65% |
100,000
-97,000
| -49% | -$17.7M |
|
42
Molina Healthcare
MOH
$11.7B
| $20.1M | 0.64% |
148,433
-48,623
| -25% | -$6.12M |
|
|
GBT
43
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $20M | 0.64% |
251,000
-17,100
| -6% | -$1.01M |
|
44
eHealth
EHTH
$47.3M
| $19.6M | 0.63% |
204,000
+94,000
| +85% | +$7.3M |
|
45
Addus HomeCare
ADUS
$2.14B
| $19.2M | 0.61% |
197,915
-55,000
| -22% | -$4.84M |
|
|
DCPH
46
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $19.2M | 0.61% |
308,000
-286,725
| -48% | -$13.6M |
|
|
SEM
47
DELISTED
Select Medical
SEM
| $18.5M | 0.59% |
1,472,179
-1,709,189
| -54% | -$18.4M |
|
48
Xeris Biopharma Holdings
XERS
$1.52B
| $18.2M | 0.58% |
2,583,291
+274,625
| +12% | +$2.27M |
|
|
FTSV
49
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $17.6M | 0.56% |
447,000
-303,000
| -40% | -$4.87M |
|
|
RVNC
50
DELISTED
Revance Therapeutics, Inc.
RVNC
| $14.6M | 0.47% |
+900,000
| New | +$14M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2019 Portfolio in Review
As of Q4 2019, Deerfield Management held 107 positions worth $3.13B, up 28% from $2.45B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Deerfield Management withdrew a net $365M in Q4 2019, closing 31 positions and reducing 25 holdings. Its most notable exit was Coherus Oncology, an estimated $31.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 71% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in AdaptHealth worth $189M.
- Deerfield Management's largest Q4 2019 buy was AdaptHealth: 17,199,888 shares worth $189M.
- Deerfield Management added most to Tandem Diabetes Care in Q4 2019, an estimated $55.9M increase.
- Deerfield Management's biggest Q4 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $57.9M.
- Deerfield Management fully exited Coherus Oncology in Q4 2019, selling an estimated $31.2M.
- Deerfield Management's ten largest holdings make up 44% of its $3.13B portfolio in Q4 2019.
- Deerfield Management opened 15 new positions and closed 31 in Q4 2019.
- Deerfield Management's portfolio value rose 28% quarter-over-quarter to $3.13B.
Based on Deerfield Management's 13F filing for Q4 2019, filed 14 Feb 2020.